keyword
MENU ▼
Read by QxMD icon Read
search

wet-amd

keyword
https://www.readbyqxmd.com/read/29772044/a-phase-1-open-label-dose-escalation-trial-to-investigate-safety-and-tolerability-of-single-intravitreous-injections-of-icon-1-targeting-tissue-factor-in-wet-amd
#1
John A Wells, Christine R Gonzales, Brian B Berger, Victor H Gonzalez, Brian D Sippy, Gabriela Burian
BACKGROUND AND OBJECTIVE: This phase 1 study evaluated the safety and tolerability of single intravitreous injections (IVIs) of ICON-1 (Iconic Therapeutics, South San Francisco, CA) in patients with neovascular age-related macular degeneration (nAMD). ICON-1 is a modified factor VIIa protein linked with the Fc portion of a human immunoglobulin G1. The molecule binds tissue factor overexpressed on choroidal neovascularization (CNV) in AMD. PATIENTS AND METHODS: Open-label, interventional, dose-escalation trial in 18 patients with CNV due to AMD, with six patients per dose cohort...
May 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29753123/photodynamic-therapy-in-combination-with-ranibizumab-versus-ranibizumab-monotherapy-for-wet-age-related-macular-degeneration-a-systematic-review-and-meta-analysis
#2
REVIEW
Yongxian Su, Jiawei Wu, Yu Gu
OBJECTIVE: To evaluate the efficacy and safety between photodynamic therapy (PDT) combined with intravitreal ranibizumab (IVR) and ranibizumab monotherapy in treating wet age-related macular degeneration (AMD). METHODS: A systematic search was performed in the PubMed, Embase, Web of Science and the Cochrane Library databases through December 31, 2017. The methodological quality of the references was evaluated according to the Cochrane quality assessment. RevMan 5...
May 9, 2018: Photodiagnosis and Photodynamic Therapy
https://www.readbyqxmd.com/read/29744763/accuracy-of-ultra-wide-field-fundus-ophthalmoscopy-assisted-deep-learning-a-machine-learning-technology-for-detecting-age-related-macular-degeneration
#3
Shinji Matsuba, Hitoshi Tabuchi, Hideharu Ohsugi, Hiroki Enno, Naofumi Ishitobi, Hiroki Masumoto, Yoshiaki Kiuchi
PURPOSE: To predict exudative age-related macular degeneration (AMD), we combined a deep convolutional neural network (DCNN), a machine-learning algorithm, with Optos, an ultra-wide-field fundus imaging system. METHODS: First, to evaluate the diagnostic accuracy of DCNN, 364 photographic images (AMD: 137) were amplified and the area under the curve (AUC), sensitivity and specificity were examined. Furthermore, in order to compare the diagnostic abilities between DCNN and six ophthalmologists, we prepared yield 84 sheets comprising 50% of normal and wet-AMD data each, and calculated the correct answer rate, specificity, sensitivity, and response times...
May 9, 2018: International Ophthalmology
https://www.readbyqxmd.com/read/29734810/theoretical-insights-into-the-retinal-dynamics-of-vegf-in-patients-treated-with-ranibizumab-based-on-an-ocular-pharmacokinetic-pharmacodynamic-model
#4
Laurence A Hutton-Smith, Eamonn A Gaffney, Helen M Byrne, Antonello Caruso, Philip K Maini, Norman Alan Mazer
Neovascular age-related macular degeneration (wet AMD) results from the pathological angiogenesis of choroidal capillaries, which leak fluid within or below the macular region of the retina. The current standard of care for treating wet AMD utilizes intravitreal injections of anti-VEGF antibodies or antibody fragments to suppress ocular VEGF levels. While VEGF suppression has been demonstrated in wet AMD patients by serial measurements of free-VEGF concentrations in aqueous humor samples, it is presumed that anti-VEGF molecules also permeate across the inner limiting membrane (ILM) of the retina as well as the retinal pigmented epithelium (RPE) and suppress VEGF-levels in the retina and/or choroidal regions...
May 7, 2018: Molecular Pharmaceutics
https://www.readbyqxmd.com/read/29721978/vegf-as-a-trophic-factor-for-m%C3%A3-ller-glia-in-hypoxic-retinal-diseases
#5
Shuhua Fu, Shuqian Dong, Meili Zhu, Yun-Zheng Le
Age-related macular degeneration (AMD) and diabetic retinopathy (DR), leading causes of blindness, share a common retinal environment: hypoxia which is a major stimulator for the upregulation of vascular endothelial growth factor (VEGF), a cardinal pathogenic factor for the breakdown of blood-retina barrier (BRB). As a result of intensive studies on VEGF pathobiology, anti-VEGF strategy has become a major therapeutics for wet AMD and DR. To investigate the potential impact of anti-VEGF strategy on major retinal supporting cells, Müller glia (MG), we disrupted VEGF receptor-2 (VEGFR2) in MG with conditional knockout (CKO) and examined the effect of VEGFR2-null on MG viability and neuronal integrity in mice...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29721942/the-role-of-hypoxia-hypoxia-inducible-factor-hif-and-vegf-in-retinal-angiomatous-proliferation
#6
Maya Barben, Marijana Samardzija, Christian Grimm
In industrialized countries, age-related macular degeneration (AMD) is the leading cause of blindness in elderly people. Hallmarks of the non-neovascular (dry) form of AMD are the formation of drusen and geographic atrophy, whereas the exudative (wet) form of the disease is characterized by invading blood vessels. In retinal angiomatous proliferation (RAP), a special form of wet AMD, intraretinal vessels grow from the deep plexus into the subretinal space. Little is known about the mechanisms leading to intraretinal neovascularization, but age-related changes such as reduction of choroidal blood flow, accumulation of drusen, and thickening of the Bruch's membrane may lead to reduced oxygen availability in photoreceptors...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29721926/anaphylatoxin-signaling-in-retinal-pigment-and-choroidal-endothelial-cells-characteristics-and-relevance-to-age-related-macular-degeneration
#7
Bärbel Rohrer
Age-related macular degeneration (AMD) is the leading cause of blindness in the USA. Polymorphisms in various complement components are associated with an increased risk for AMD, and it has been hypothesized that an overactive complement system is partially responsible for the pathology of AMD. AMD is classified as early, intermediate, or late AMD, depending on the degree of the associated pathologies. Late AMD can be characterized as either lesions associated with neovascular AMD or geographic atrophy. Both sets of lesions are associated with pathology at the RPE/choroid interface, which include a thickening of Bruch's membrane, presence of drusen, and pigmentary alterations, and deterioration of the blood-retina barrier has been reported...
2018: Advances in Experimental Medicine and Biology
https://www.readbyqxmd.com/read/29696386/tear-film-proteome-in-age-related-macular-degeneration
#8
Mateusz Winiarczyk, Kai Kaarniranta, Stanisław Winiarczyk, Łukasz Adaszek, Dagmara Winiarczyk, Jerzy Mackiewicz
PURPOSE: Age-related macular degeneration (AMD) is the main reason for blindness in elderly people in the developed countries. Current screening protocols have limitations in detecting the early signs of retinal degeneration. Therefore, it would be desirable to find novel biomarkers for early detection of AMD. Development of novel biomarkers would help in the prevention, diagnostics, and treatment of AMD. Proteomic analysis of tear film has shown promise in this research area. If an optimal set of biomarkers could be obtained from accessible body fluids, it would represent a reliable way to monitor disease progression and response to novel therapies...
April 25, 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29682574/baseline-predictors-of-visual-acuity-outcome-in-patients-with-wet-age-related-macular-degeneration
#9
REVIEW
Xinyuan Zhang, Timothy Y Y Lai
Age-related macular degeneration (AMD) is one of the leading causes of severe vision loss in people over 60 years. Wet AMD (wAMD) causes more severe visual acuity (VA) loss compared with the dry form due to formation of choroidal neovascularization (CNV). Antivascular endothelial growth factor (anti-VEGF) agents such as ranibizumab and aflibercept are now the standard of care treatment for wAMD. Unfortunately, up to a quarter of anti-VEGF-treated wAMD patients might not fully benefit from intravitreal injections and CNV activity may not respond to the treatment and these patients are called anti-VEGF nonresponders...
2018: BioMed Research International
https://www.readbyqxmd.com/read/29619125/accuracy-of-a-self-monitoring-test-for-identification-and-monitoring-of-age-related-macular-degeneration-a-diagnostic-case-control-study
#10
Martin K Schmid, Livia Faes, Lucas M Bachmann, Michael A Thiel
Objective: To evaluate diagnostic accuracy of a new self-monitoring device using a Vernier hyperacuity alignment task. Method: A total of 11 wet Age-Related Macular Degeneration (AMD) patients and 9 controls contributing 37 eyes were consecutively enrolled into this prospective diagnostic case-control study at the retina centre of the Cantonal Hospital Lucerne, Switzerland. Vernier acuity testing (index test) and Optical Coherence Tomography (OCT, reference test) were performed in all participants...
2018: Open Ophthalmology Journal
https://www.readbyqxmd.com/read/29616508/an-efficacy-analysis-of-anti-vascular-endothelial-growth-factor-therapy-for-choroidal-neovascularization-secondary-to-multifocal-choroiditis-and-comparison-with-wet-age-related-macular-degeneration
#11
Lei Feng, Jiang-Hua Hu, Jie Chen, Xin Xie
OBJECTIVE: To evaluate the effect of anti-vascular endothelial growth factor (VEGF) on juxtafoveal choroidal neovascularization (CNV) secondary to multifocal choroiditis (MFC) and wet age-related macular degeneration (AMD). METHODS: In this retrospective, comparative study, 20 unique eyes with CNV were divided into two groups: 10 patients affected by MFC and 10 patients diagnosed with wet AMD. They all received local intravitreal (IVT) injections of ranibizumab, with 6 months of follow-up...
2018: Journal of Zhejiang University. Science. B
https://www.readbyqxmd.com/read/29559434/patients-with-severe-wet-amd-regain-vision-after-stem-cell-treatment
#12
Abi Rimmer
No abstract text is available yet for this article.
March 20, 2018: BMJ: British Medical Journal
https://www.readbyqxmd.com/read/29554386/appointment-compliance-in-patients-with-diabetic-macular-edema-and-exudative-macular-degeneration
#13
Michael E Jansen, Chelsey J Krambeer, Daniel S Kermany, Jana N Waters, Wayne Tie, Sepehr Bahadorani, Julia Singer, Jordan M Comstock, Kendall W Wannamaker, Michael A Singer
BACKGROUND AND OBJECTIVE: The purpose of this study is to compare cancellation and no-show rates in patients with diabetic macular edema (DME) and exudative macular degeneration (wet AMD). PATIENTS AND METHODS: An anonymous survey was sent to 1,726 retina specialists inquiring as to the number of appointments their patients with DME and wet AMD attended, cancelled, or did not show up for in 2014 and 2015. RESULTS: Data were obtained on 109,599 appointments...
March 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29484559/the-effect-of-non-neovascular-age-related-macular-degeneration-on-face-recognition-performance
#14
COMPARATIVE STUDY
Deanna J Taylor, Nicholas D Smith, Alison M Binns, David P Crabb
PURPOSE: There is a well-established research base surrounding face recognition in patients with age-related macular degeneration (AMD). However, much of this existing research does not differentiate between results obtained for 'wet' AMD and 'dry' AMD. Here, we test the hypothesis that face recognition performance is worse in patients with dry AMD compared with visually healthy peers. METHODS: Patients (>60 years of age, logMAR binocular visual acuity 0.7 or better) with dry AMD of varying severity and visually healthy age-related peers (controls) completed a modified version of the Cambridge Face Memory Test (CFMT)...
April 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29451077/intravitreal-aflibercept-versus-ranibizumab-for-wet-age-related-macular-degeneration-a-cost-effectiveness-analysis
#15
Luis Hernandez, Tereza Lanitis, Clifford Cele, Hector Toro-Diaz, Andrea Gibson, Andreas Kuznik
BACKGROUND: Age-related macular degeneration (AMD) is the leading cause of vision loss in the United States. The most severe vision loss occurs in patients with neovascular AMD, known as wet AMD (wAMD). The most commonly used antivascular endothelial growth factor (VEGF) therapies approved by the FDA to treat patients with wAMD are ranibizumab, 0.5 mg administered by intravitreal injection once a month (approximately every 28 days), and intravitreal aflibercept injection (IAI), 2 mg every 4 weeks (monthly) for the first 12 weeks (3 months), followed by IAI 2 mg once every 8 weeks (2 months)...
February 16, 2018: Journal of Managed Care & Specialty Pharmacy
https://www.readbyqxmd.com/read/29446046/anti-neovascularization-effects-of-dmbt-in-age-related-macular-degeneration-by-inhibition-of-vegf-secretion-through-ros-dependent-signaling-pathway
#16
Shang Chen, Yue Zhou, Lichun Zhou, Yanhui Guan, Yu Zhang, Xiuzhen Han
Choroidal neovascularization (CNV) is the hallmark of late-staged wet age-related macular degeneration (AMD). Vascular endothelial growth factor (VEGF) is a key component in the development and progression of wet AMD. DMBT, 6,6'-bis(2,3-dimethoxybenzoyl)-α,α-D-trehalose, had been proved that it could suppress tumor angiogenesis and metastasis by inhibiting production of VEGF. But the effects of DMBT on CNV were not known. This study was to investigate effects and mechanisms of DMBT on CNV in vitro and in vivo...
February 14, 2018: Molecular and Cellular Biochemistry
https://www.readbyqxmd.com/read/29443357/low-energy-stereotactic-radiotherapy-for-treatment-of-exudative-age-related-macular-degeneration-in-a-treat-and-extend-regimen
#17
Katja Hatz, Frank Zimmermann, Dimitrios Kardamakis, Emmanouil Lazaridis, Cengiz Türksever, Jörg Binder, Alexandros Papachristofilou, Christian Prünte
BACKGROUND AND OBJECTIVE: To evaluate the effectiveness and safety of low-energy stereotactic radiotherapy (SRT) combined with anti-vascular endothelial growth factor (VEGF) treatment following a treat-and-extend regimen (TER) in wet age-related macular degeneration (AMD). PATIENTS AND METHODS: Before/after SRT, the authors compared retrospective consecutive case series of 50 patients requiring frequent anti-VEGF treatment (every 4 or 6 weeks) in wet AMD, treated with a single session of SRT and TER (same manner pre/post-SRT)...
February 1, 2018: Ophthalmic Surgery, Lasers & Imaging Retina
https://www.readbyqxmd.com/read/29424830/what-is-the-nature-of-the-reach-and-grasp-deficit-in-wet-age-related-macular-degeneration
#18
Xavier Corveleyn, Quentin Lenoble, Sébastien Szaffarczyk, Thi Ha Chau Tran, Muriel Boucart
SIGNIFICANCE: Vision is paramount for motor actions directed toward objects. Vision allows not only the identification of objects and their shape and spatial location, but also the adaptation of our movement when it arrives on the object. These findings show that vision deficits, as in age-related macular degeneration (AMD), can lead to reaching and grasping deficits. PURPOSE: Few studies have investigated reaching and grasping in patients with AMD. They showed a deficit in the execution of motor actions in people with AMD, even though these people do not mention difficulties in their daily lives...
March 2018: Optometry and Vision Science: Official Publication of the American Academy of Optometry
https://www.readbyqxmd.com/read/29397436/the-fate-of-eyes-with-wet-amd-beyond-four-years-of-anti-vegf-therapy
#19
Justus G Garweg, Johanna J Zirpel, Christin Gerhardt, Isabel B Pfister
PURPOSE: Real-life studies on long-term functional outcome of anti-VEGF treatment for wet age-related macular degeneration (wAMD) are limited. We therefore assessed the 10-year outcomes in our patients. METHODS: In this retrospective study, all patients with newly diagnosed wAMD that had received minimally three intravitreal injections between 2007 and 2012 and a follow-up of ≥48 months were included. Primary outcome measure was the evolution of best-corrected visual acuity (BCVA) over time...
April 2018: Graefe's Archive for Clinical and Experimental Ophthalmology
https://www.readbyqxmd.com/read/29367267/doctors-are-cleared-to-prescribe-cheaper-drug-for-wet-amd
#20
Deborah Cohen
No abstract text is available yet for this article.
January 24, 2018: BMJ: British Medical Journal
keyword
keyword
53816
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"